$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

$shph Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032276 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022 Q2
Revenue	$0.00		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$301.1K	$152.4K	$269.8K
YoY Change	-44.9%	176.34%	439.52%
% of Gross Profit
Research & Development	$439.7K	$669.0K	$83.87K
YoY Change	-0.55%	257.85%	-71.08%
% of Gross Profit
Depreciation & Amortization	$1.490K	$1.580K	$1.450K
YoY Change	-31.34%	-115.11%
% of Gross Profit
Operating Expenses	$740.8K	$821.5K	$353.6K
YoY Change	-25.06%	239.29%	4.01%
Operating Profit		-$821.5K	-$353.6K
YoY Change		239.29%
Interest Expense	-$10.12K	-$505.6K	-$243.7K
YoY Change	-101.91%	1253.79%	2336.5%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$177.0K	-$243.6K
YoY Change		-803.47%
Pretax Income	-$750.9K	-$998.4K	-$597.3K
YoY Change	63.58%	360.19%	70.65%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$750.9K	-$998.4K	-$597.3K
YoY Change	54.89%	360.19%	72.22%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.10	-$0.06
Diluted Earnings Per Share	-$0.06	-$0.07	-$0.05
COMMON SHARES
Basic Shares Outstanding	13.59M shares	10.16M shares	9.313M shares
Diluted Shares Outstanding			9.313M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.417M	$9.120M	$50.44K
YoY Change
Cash & Equivalents	$8.417M	$9.120M	$50.44K
Short-Term Investments
Other Short-Term Assets	$161.2K	$163.1K	$13.52K
YoY Change
Inventory
Prepaid Expenses	$161.1K
Receivables		$5.954K
Other Receivables		$0.00
Total Short-Term Assets	$8.578M	$9.289M	$63.95K
YoY Change	1583.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.59K	$14.08K	$103.1K
YoY Change	-32.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.480K	$6.480K	$6.480K
YoY Change
Total Long-Term Assets	$75.19K	$92.53K	$109.5K
YoY Change	-47.06%
TOTAL ASSETS
Total Short-Term Assets	$8.578M	$9.289M	$63.95K
Total Long-Term Assets	$75.19K	$92.53K	$109.5K
Total Assets	$8.654M	$9.382M	$173.5K
YoY Change	1227.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$116.8K	$107.2K	$515.8K
YoY Change
Accrued Expenses	$173.5K	$177.8K	$181.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$685.5K	$685.5K	$1.261M
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$975.7K	$970.5K	$2.454M
YoY Change	-56.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$6.670K	$25.60K
YoY Change
Total Long-Term Liabilities	$0.00	$6.670K	$25.60K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$975.7K	$970.5K	$2.454M
Total Long-Term Liabilities	$0.00	$6.670K	$25.60K
Total Liabilities	$975.7K	$977.1K	$2.480M
YoY Change	-57.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.895M	-$8.144M
YoY Change	53.48%
Common Stock	$16.57M	$16.55M
YoY Change	299.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.678M	$8.405M	-$2.306M
YoY Change
Total Liabilities & Shareholders Equity	$8.654M	$9.382M	$173.5K
YoY Change	1227.96%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022 Q2
OPERATING ACTIVITIES
Net Income	-$750.9K	-$998.4K	-$597.3K
YoY Change	54.89%	360.19%	72.22%
Depreciation, Depletion And Amortization	$1.490K	$1.580K	$1.450K
YoY Change	-31.34%	-115.11%
Cash From Operating Activities	-$679.9K	-$1.051M	-$355.4K
YoY Change	403.04%	857.84%	788.55%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-23.32K	10.12M	0.000
YoY Change	-104.71%	6080.09%
NET CHANGE
Cash From Operating Activities	-679.9K	-1.051M	-355.4K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	-23.32K	10.12M	0.000
Net Change In Cash	-703.2K	9.070M	-355.4K
YoY Change	-295.45%	16671.36%	788.55%
FREE CASH FLOW
Cash From Operating Activities	-$679.9K	-$1.051M	-$355.4K
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$1.051M	-$355.4K
YoY Change		857.84%	788.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001757499
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2022Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent		usd
CY2022Q3	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent		usd
CY2022Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent		usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	SHPH	Common Stock To Be Issued CommonStockToBeIssued		usd
CY2021Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	SHPH	Common Stock Issued For Conversion Of Convertible Debt CommonStockIssuedForConversionOfConvertibleDebt		usd
	SHPH	Common Stock Issued For Exercise Of Warrants With Settlement Of Notes Payable CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable		usd
	SHPH	Common Stock Issued For Dividend Payable CommonStockIssuedForDividendPayable		usd
CY2022Q3	us-gaap	Notes Payable NotesPayable		usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet		usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41488
	dei	Entity Registrant Name EntityRegistrantName	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5089826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	One Research Court
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 450
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
	dei	City Area Code CityAreaCode	(240)
	dei	Local Phone Number LocalPhoneNumber	403-4212
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	SHPH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13586393	shares
CY2022Q3	us-gaap	Cash Cash	9120390	usd
CY2021Q4	us-gaap	Cash Cash	504749	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	163142	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4866	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5954	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	9289486	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	509615	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14080	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18564	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	6480	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	6480	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	71970	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	116982	usd
CY2022Q3	us-gaap	Assets Assets	9382016	usd
CY2021Q4	us-gaap	Assets Assets	651641	usd
CY2022Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	107153	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	828313	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18904	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	552	usd
CY2022Q3	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	85233	usd
CY2021Q4	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	46947	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	331059	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	685473	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	685473	usd
CY2021Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	91021	usd
CY2021Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	73007	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	94025	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	73707	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	66934	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	970470	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2217331	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6671	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62442	usd
CY2022Q3	us-gaap	Liabilities Liabilities	977141	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2279773	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13586393	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13586393	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9312152	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9312152	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	136	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	93	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16548719	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4150867	usd
CY2021Q4	SHPH	Common Stock To Be Issued CommonStockToBeIssued	16340	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8143980	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5795432	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8404875	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1628132	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9382016	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	651641	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	669038	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	186958	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1048821	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	579684	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	81864	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6422	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104711	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19883	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	70566	usd
CY2021Q3	us-gaap	Legal Fees LegalFees	48736	usd
	us-gaap	Legal Fees LegalFees	659958	usd
	us-gaap	Legal Fees LegalFees	154886	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	821468	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	242116	usd
	us-gaap	Operating Expenses OperatingExpenses	1813490	usd
	us-gaap	Operating Expenses OperatingExpenses	754453	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-821468	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-242116	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1813490	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-754453	usd
CY2022Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	13725	usd
CY2021Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	10547	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	39108	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	31641	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	604716	usd
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	113	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	920660	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	463	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-112797	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	26685	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-94025	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30971	usd
CY2022Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	328687	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	328687	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	62500	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	73007	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	62500	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-176957	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25155	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-464049	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	61367	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-998425	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-216961	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2277539	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-693086	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-998425	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-216961	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2277539	usd
	us-gaap	Net Income Loss NetIncomeLoss	-693086	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	19473	usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	25768	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	71009	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	77304	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1017898	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-242729	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2348548	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-770390	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10164979	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9291526	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9723510	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9298332	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1628132	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	319643	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	166533	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-681839	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1849563	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	166533	usd
CY2022Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-597275	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2306073	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10031415	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14098	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	92598	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	588524	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	588524	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	576476	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	23667	usd
CY2022Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	19473	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	402068	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-998425	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8404875	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1690296	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	122517	usd
CY2021Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-129324	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-1722871	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	122517	usd
CY2021Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-346801	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1972923	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1972923	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	122517	usd
CY2021Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-216961	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-2093135	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-2093135	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2277539	usd
	us-gaap	Net Income Loss NetIncomeLoss	-693086	usd
	us-gaap	Depreciation Depreciation	4484	usd
	us-gaap	Depreciation Depreciation	4050	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-94025	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30971	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	45012	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	40408	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	885505	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	328687	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	73007	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	62500	usd
	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	-12625	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	356733	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	367551	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5954	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-211455	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	158276	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-5281	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-392473	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3646	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	5727	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	270	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	38286	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	31641	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-48998	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-42930	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2030587	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-165185	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10045513	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	50000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	120000	usd
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	73007	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	600715	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10646228	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	193007	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8615641	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27822	usd
	us-gaap	Stock Issued1 StockIssued1	16340	usd
	SHPH	Common Stock Issued For Conversion Of Convertible Debt CommonStockIssuedForConversionOfConvertibleDebt	588524	usd
	SHPH	Common Stock Issued For Exercise Of Warrants With Settlement Of Notes Payable CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable	576476	usd
	SHPH	Common Stock Issued For Dividend Payable CommonStockIssuedForDividendPayable	402067	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	504749	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	117153	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9120390	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	144975	usd
	us-gaap	Interest Paid Net InterestPaidNet	17489	usd
	us-gaap	Interest Paid Net InterestPaidNet	293	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	2-for-1 reverse stock split
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zpXJXRl7uZni" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zPEiyQuA66c7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying financial statements include useful lives of property and equipment, valuation of derivatives, and the valuation allowance on deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020	SHPH	Proceeds From Contract Awards For Research And Development ProceedsFromContractAwardsForResearchAndDevelopment	845820	usd
CY2022Q2	SHPH	Payments To Invoices In Research And Development PaymentsToInvoicesInResearchAndDevelopment	791017	usd
CY2022Q3	SHPH	Payments To Invoices In Research And Development PaymentsToInvoicesInResearchAndDevelopment	282643	usd
	SHPH	Research And Development Deficit Net ResearchAndDevelopmentDeficitNet	83868	usd
CY2022Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	94025	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	127466	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	127466	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	113386	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	145593	shares
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	108902	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14080	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18564	usd
	us-gaap	Depreciation Depreciation	4484	usd
	us-gaap	Depreciation Depreciation	4050	usd
	us-gaap	Lessee Operating Lease Assumptions And Judgments Discount Rate Description LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription	The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of our leases is not readily determinable.
	us-gaap	Operating Lease Expense OperatingLeaseExpense	52631	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	52445	usd
CY2018Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	6291	usd
CY2018Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2018Q4	us-gaap	Security Deposit SecurityDeposit	6480	usd
CY2022Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2022Q3	SHPH	Office Lease OfficeLease	265207	usd
CY2021Q4	SHPH	Office Lease OfficeLease	265207	usd
CY2022Q3	SHPH	Accumulated Amortization On Right Of Use Assets AccumulatedAmortizationOnRightOfUseAssets	193237	usd
CY2021Q4	SHPH	Accumulated Amortization On Right Of Use Assets AccumulatedAmortizationOnRightOfUseAssets	148225	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	71970	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	116982	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	80378	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	129376	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	73707	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	66934	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6671	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62442	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	19440	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64800	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	84240	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3862	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	80378	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	In December of 2021 the maturity dates of these loans were extended to June 30, 2022. In July of 2022 the notes were extended to June 30, 2023
CY2021Q2	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	In July of 2022 the notes were extended to June 30, 2023
CY2021Q1	us-gaap	Medium Term Notes MediumTermNotes	73007	usd
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01	pure
CY2021Q1	us-gaap	Short Term Debt Description ShortTermDebtDescription	No more than 25% of the amount forgiven can be attributable to non-payroll costs.
CY2020Q2	us-gaap	Medium Term Notes MediumTermNotes	62500	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01	pure
CY2020Q2	us-gaap	Short Term Debt Description ShortTermDebtDescription	No more than 25% of the amount forgiven can be attributable to non-payroll costs.
CY2022Q3	SHPH	Loan Forgiveness LoanForgiveness	-73007	usd
CY2021Q4	SHPH	Loan Forgiveness LoanForgiveness	-62500	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	73007	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	500000	usd
CY2021Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-12-28
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	500000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.00
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	5075	usd
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16667	usd
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	365000	usd
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	224985	usd
CY2022Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.06	pure
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.06	pure
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.50	pure
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.50	pure
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	36500	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	22250	usd
	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	-12625	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	125000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	30000	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	500000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	408979	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	91021	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	408979	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	3.60
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13586393	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13586393	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9312152	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9312152	shares
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1407262	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	197273	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	180280	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	336810	shares
CY2018Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	120250	usd
CY2022Q3	us-gaap	Share Price SharePrice	13.88
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	13.88
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	20.82
	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	12.49
	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	13.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.855	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.085	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y3M29D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0073	pure
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	197273	shares

Files In Submission

Name	View Source	Status
0001493152-22-032276-index-headers.html	Edgar Link	pending
0001493152-22-032276-index.html	Edgar Link	pending
0001493152-22-032276.txt	Edgar Link	pending
0001493152-22-032276-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
shph-20220930.xsd	Edgar Link	pending
shph-20220930_def.xml	Edgar Link	unprocessable
shph-20220930_cal.xml	Edgar Link	unprocessable
shph-20220930_lab.xml	Edgar Link	unprocessable
shph-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2022 Q4 Form 10-Q Financial Statement

#000149315222032276 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2022 Q4 Form 10-Q Financial Statement

#000149315222032276 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph